| Prev Close | 268.35 |
| Open | 265.51 |
| Day Low/High | 263.78 / 268.00 |
| 52 Wk Low/High | 176.36 / 292.75 |
| Volume | 323.61K |
Vertex Pharmaceuticals Incorporated (VRTX)
264.33
4.00
1.50
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 255.76B |
| Market Cap | 66.14B |
| P/E Ratio | 23.27 |
| Div & Yield | N.A. (N.A) |
Early-Morning Market Look
Let's start by taking a peek at the overnight and early-morning price action of the major asset classes. The rundown: S&P futures -4; Nasdaq futures -; Nikkei schmeissed for second day in a row, -3% and at the lowest level in three weeks (is Abe ret...
Is Stock Picking Impossible This Year?
Stick with solid investing precepts.
Individuals Stand Strong
We are seeing some hot pockets of momentum.
The Bears Get Fed
No setup for a bullish reaction to bullish news today.
A Market With No Memory
It can turn so quickly and totally forget poor action.
Feels Like a Bear Market
The best thing to do is get out of the way and let it play out.
The Action Has Shifted
And the close put an exclamation point on it.
Biotech's Next Big Thing: Vertex
TheStreet senior columnist Adam Feuerstein explains why Vertex Pharmaceuticals is the next big thing in biotech.
Still Plenty of Buying Interest
Action in individual stocks was impressive despite the struggling indices.
A One-Way Market
The action just keeps chugging higher.
Working for the Weekend
I'm going to spend some time developing my watch list for next week.
Futures Point Higher; Boston Manhunt Plays Out
US stock futures are up amid earnings from GE and IBM. TheStreet's Debra Borchardt details.
The Next Big Thing in Biotech: Earnings
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
A Market in Limbo
Traders are jockeying for position as we await the Fed, economic data and key earnings.
The Next Big Thing in Biotech: Dendreon/Vertex Earnings
Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.
The Next Big Thing In Biotech: Vertex
Adam Feuerstein, Sr. Columnist for TheStreet, says Vertex Pharmaceuticals is the next big thing in biotech.
